Maleimide

CAS No. 541-59-3

Maleimide( 25-Pyrroledione )

Catalog No. M19624 CAS No. 541-59-3

Maleimide (25-Pyrroledone) is a new nanoparticle surface functional group which favors easy conjugation with cell penetration peptides. The conjugation is enabled via click chemistry to preserve its biofunctions.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G 27 In Stock

Biological Information

  • Product Name
    Maleimide
  • Note
    Research use only, not for human use.
  • Brief Description
    Maleimide (25-Pyrroledone) is a new nanoparticle surface functional group which favors easy conjugation with cell penetration peptides. The conjugation is enabled via click chemistry to preserve its biofunctions.
  • Description
    Maleimide (25-Pyrroledone) is a new nanoparticle surface functional group which favors easy conjugation with cell penetration peptides. The conjugation is enabled via click chemistry to preserve its biofunctions.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    25-Pyrroledione
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    541-59-3
  • Formula Weight
    97.07
  • Molecular Formula
    C4H3NO2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:10 mM
  • SMILES
    O=C1NC(=O)C=C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Feng G et al. Bright single-chain conjugated polymer dots embedded nanoparticles for long-term cell tracing and imaging. Small. 2014 Mar 26;10(6):1212-9.
molnova catalog
related products
  • RS 42358-197

    RS 42358-197 is the S-isomer of RS-42358, which is the novel 5-HT3 receptor antagonist.

  • Isoliensinine Hydro...

    Isoliensinine Hydrochloride

  • GDC-1971

    Migoprotafib (GDC-1971) (compound 199) is a SHP2 inhibitor. Migoprotafib inhibits the MAPK/ERK signaling pathway, and exhibits antitumor activity.